EPA DHA Ethyl Ester Parenteral Emulsion Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current parenteral lipid emulsions containing omega-3 fatty acids face stability issues and require high dosages due to low concentrations, leading to potential health effects from excessive cholesterol and saturated fatty acid intake, while existing formulations often include unstable components like medium chain triglycerides.
Innovation Solution
A composition comprising an aqueous phase and 5-30% oil phase with omega-3 fatty acid ethylesters, specifically eicosapentaenoic acid ethylester and docosahexaenoic acid ethylester, combined with anionic and amphoteric surfactants, and minimal oleic acid, which is stable and allows for higher omega-3 concentrations without medium chain fatty acid derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If fish oil is used as the lipid source in parenteral emulsions, then omega-3 fatty acid content is improved, but emulsion stability deteriorates due to high proportions of omega-6 fatty acids and susceptibility to lipid peroxidation
Solution Approach 1:
The patent changes the chemical form of omega-3 fatty acids from natural triglycerides in fish oil to ethyl ester derivatives. This parameter change (molecular structure modification) increases the omega-3 content to 50-90% of the oil phase while reducing susceptibility to peroxidation. The ethyl ester form provides greater oxidative stability while maintaining the beneficial anti-inflammatory and immune-modulating effects of omega-3 fatty acids.
Solution Approach 2:
The patent creates a composite lipid emulsion system combining ethyl ester omega-3 fatty acids with specific emulsifiers (phospholipids, cholesterol, and protein components) and antioxidants. This composite formulation enhances overall emulsion stability through synergistic interactions between components, where the ethyl ester omega-3 provides structural stability and the combined emulsifier system maintains interfacial integrity.
2Quantity of substance
If high dosages are administered to achieve therapeutic omega-3 levels, then omega-3 fatty acid intake is improved, but adverse health effects worsen due to excessive cholesterol and saturated fatty acid intake
Solution Approach 1:
The patent extracts and isolates omega-3 fatty acids from their natural fish oil matrix, separating them from accompanying cholesterol and saturated fatty acids. By using purified ethyl ester omega-3 derivatives as the sole or primary lipid source, the formulation delivers high omega-3 intake (50-90% of oil phase) without the harmful components that would otherwise be present in natural fish oil, allowing therapeutic dosing without adverse effects.
Solution Approach 2:
The patent applies local quality by creating a lipid emulsion with non-uniform composition where the oil phase is highly enriched (50-90%) with omega-3 ethyl esters rather than the typical 10-30% found in conventional fish oil emulsions. This localized concentration of omega-3 in the lipid phase allows for reduced overall dosage while achieving therapeutic effects, because the omega-3 content per unit volume is significantly higher.
3Stability of the object's composition
If medium chain triglycerides are included in the emulsion formulation, then emulsion stability is improved, but reliability worsens due to instability of medium chain fatty acid derivatives
Solution Approach 1:
The patent replaces unstable medium chain triglycerides with stable ethyl ester omega-3 fatty acids as the primary lipid component. The ethyl ester form acts as a more reliable, long-term stable alternative to the short-lived, oxidation-prone medium chain triglycerides, while still providing the desired emulsion stability through its molecular structure and interaction with the emulsifier system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves enhanced stability and reduced necessary dosage, providing a higher concentration of omega-3 fatty acids, thereby improving bioavailability and minimizing adverse health effects.
Implementation Method 1
the composition further comprises at least one anionic surfactant and at least one amphoteric surfactant
Implementation Method 2
the high number of double bonds in omega-6 fatty acids makes them prone to lipid peroxidation
Data Source
AI summary
Described herein are compositions for parenteral administration that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid ethylesters eicosapentaenoic acid ethylester, docosahexaenoic acid ethylester, and mixtures thereof. The composition further comprises at least one anionic surfactant and at least one amphoteric surfactant, and less than 0.05% by weight of oleic acid, based on the total weight of the composition. Also described is a method for preparing such a composition as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimer's disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need thereof and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.